2026-05-17T00:18:16Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/184732024-11-28T15:11:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16981
Repisalud
author
Kuchay, Mohammad Shafi
author
Martínez-Montoro, José Ignacio
author
Choudhary, Narendra Singh
author
Fernández-García, José Carlos
author
Ramos-Molina, Bruno
authoraffiliation
[Kuchay,MS] Division of Endocrinology and Diabetes, Medanta The Medicity Hospital, Gurugram, Haryana, India. [Martínez-Montoro,JI] Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Malaga (IBIMA), Faculty of Medicine, University of Malaga, Malaga, Spain. [Choudhary,NS] Department of Hepatology, Medanta The Medicity Hospital, Gurugram, Haryana, India. [Fernández-García,JC] Department of Endocrinology and Nutrition, Regional University Hospital of Malaga, Institute of Biomedical Research in Malaga (IBIMA), Faculty of Medicine, University of Malaga, Malaga, Spain. [Ramos-Molina,B] Obesity and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain.
2024-02-19T15:31:34Z
2024-02-19T15:31:34Z
2021-09-28
10.3390/biomedicines9101346
2227-9059
Biomedicines
http://hdl.handle.net/10668/3641
34680463
http://hdl.handle.net/20.500.12105/18473
Non-alcoholic fatty liver disease (NAFLD), which approximately affects a quarter of the world's population, has become a major public health concern. Although usually associated with excess body weight, it may also affect normal-weight individuals, a condition termed as lean/non-obese NAFLD. The prevalence of lean/non-obese NAFLD is around 20% within the NAFLD population, and 5% within the general population. Recent data suggest that individuals with lean NAFLD, despite the absence of obesity, exhibit similar cardiovascular- and cancer-related mortality compared to obese NAFLD individuals and increased all-cause mortality risk. Lean and obese NAFLD individuals share several metabolic abnormalities, but present dissimilarities in genetic predisposition, body composition, gut microbiota, and susceptibility to environmental factors. Current treatment of lean NAFLD is aimed at improving overall fitness and decreasing visceral adiposity, with weight loss strategies being the cornerstone of treatment. Moreover, several drugs including PPAR agonists, SGLT2 inhibitors, or GLP-1 receptor agonists could also be useful in the management of lean NAFLD. Although there has been an increase in research regarding lean NAFLD, there are still more questions than answers. There are several potential drugs for NAFLD therapy, but clinical trials are needed to evaluate their efficacy in lean individuals.
eng
Lean NAFLD
Visceral adiposity
Insulin resistance
Gut microbiota
Metabolic syndrome
Adiposidad
Resistencia a la insulina
Microbioma gastrointestinal
Síndrome metabólico
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
review article